Bayer's Prostate Data and China Approval Lift the Stock, but JPMorgan's 61-Euro Target Is Still a Bet on the Future
Published on 10/29/2026 at 15:31 | Editorial boerse-global.de
Bayer shares climbed 3.2% on Monday, powered by two developments that arrived within days of each other: a closely watched prostate cancer readout and a Chinese regulatory green light. JPMorgan added its voice the same day, reaffirming an "Overweight" rating and a EUR 61 price target. Analyst Richard Vosser took a positive view of the DASL-HiCaP interim results. That endorsement supports the optimistic case — but it is an analyst's assessment, not evidence of business figures already booked.
What the DASL-HiCaP interim analysis actually showed
Bayer released the Phase III data on Saturday. Darolutamid, marketed as Nubeqa, cut the combined risk of metastases or death by 58% versus placebo when added to hormone therapy and radiotherapy. The four-year metastasis-free survival rate came in at 95%, against 88% in the placebo arm. The trial enrolled prostate cancer patients at high risk of recurrence who were also receiving androgen deprivation therapy and radiation.
Two caveats belong alongside those numbers. The findings stem from an interim analysis, not the final readout of the study. And the 58% figure applies to the combined endpoint of metastases or death in the specific treatment setting studied — it cannot be extrapolated wholesale to other patient groups. The result describes a clinical benefit, not a revenue increase or an improvement in earnings.
A completed approval, a clinical signal, and a subgroup analysis
The three pieces of news carry different weight, and investors would do well to keep them apart. Asundexian's Chinese approval is a finished regulatory step: on Monday the NMPA cleared the drug under the brand name Sunharbo via an accelerated pathway, for adults after a non-cardioembolic ischemic stroke or high-risk TIA, to reduce stroke risk. Bayer called it the first factor XIa inhibitor available in China. That approval covers one specific market and one specific indication — it says nothing about filings elsewhere.
Should investors sell immediately? Or is it worth buying Bayer?
Finerenon offers a third data point of a different kind. On October 22, Bayer presented subgroup analyses from the Phase III FIND-CKD trial at ASN Kidney Week 2026, covering chronic kidney disease patients without diabetes. Consistent effects on proteinuria and kidney function decline were reported versus placebo. Taken together, the three developments could shore up confidence in the pharmaceutical outlook — though that would be an appraisal of several medical advances, not a demonstrated improvement in results.
The bear case isn't about the science
The serious counterargument concerns not the reported results but the weight they deserve in an investment decision. Investors can judge the medical progress correctly and still attach excessive commercial expectations to it. A convincing effect in a trial does not automatically answer the question of future financial contribution. The bearish scenario is therefore a re-rating of inflated hopes: even with the medical findings unchanged and positive, the economic interpretation could turn more cautious. Anyone judging Bayer primarily on this news should separate proven treatment effect, regulatory progress, and expected business performance.
November 3 is the next real test
Bayer reports third-quarter 2026 figures on November 3, the same day it has scheduled an investor video call and a media briefing. The date offers the next concrete occasion to weigh medical optimism against actual business development — but it is no proof that the recent drug news will already show up in the numbers. dpa-AFX attributed Monday morning's sharp share price gain to both the China approval and the positive Nubeqa data.
As long as expectations account for the differing stages of each compound, the positive findings can support a constructive view. Should the assumption of rapid commercial conversion falter, a more cautious valuation would follow. The decision facing investors, then, is not whether to acknowledge the medical progress — it is what price to put on its future significance.
Ad
Bayer Stock: New Analysis - 29 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
